Fulcrum Therapeutics® Reports Recent Business Highlights and Third Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
Fulcrum Therapeutics Inc. (FULC) Tops Q3 EPS by 8c; Cash and Cash Equivalents of $240.3M
November 4, 2021 7:21 AM EDTFulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q3 EPS of ($0.57), $0.08 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $4.9 million versus the consensus estimate of $2.25 million.
For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.
... More